Table 3.

Effects of angiogenesis modulators on angiogenesis and obesity.

Angiogenesis Modulator	Angiogenesis	Obesity	Mouse Model
TNP-470	Methionine aminopeptidases ↓, proliferation of endothelial cells ↓, angiogenesis ↓, vascular growth ↓	Body weight ↓, proliferation of 3T3-L1 preadipocytes ↓	HFD-fed, Ay, Cpefat, and ob/ob mice
CKD-732 (TNP-470 analogue)	Methionine aminopeptidases ↓, proliferation of endothelial cells ↓	Body weight ↓, fat mass ↓, adipocyte size ↓	Arcuate nucleus lesion and ob/ob mice, SD rats, and OLETF rats
Galardin	MMP activity ↓	Gonadal adipose tissue mass ↓	HFD mice
BAY 12-9566	MMP activity ↓, bFGF-induced angiogenesis ↓	Body weight ↓	Ob/ob mice
Thalidomide	bFGF-induced angiogenesis ↓, neovascularization ↓	Body weight ↓	Ob/ob mice
VEGFR blockers	Angiogenesis ↓, fat vessel ↓	Adipogenesis ↓, fat tissue expansion ↓, body weight ↓	HFD mice

bFGF, basic FGF; FGF, fibroblast growth factor; HFD, high-fat diet; MMP, matrix metalloproteinase; OLETF, Otsuka Long-Evans Tokushima fatty; SD, Sprague Dawley; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.